Axsome Therapeutics Provides Year End 2018 Clinical Update

Posted December 27, 2018 by CognitionDev

filed under: Nasdaq

In the News

Feb 20, 2020

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

Feb 19, 2020

Axsome Therapeutics to Present at Upcoming Investor Conferences

Jan 22, 2020

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

See All News